Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'en:mine regimen'
(id=6899328 ; fe=en:mine regimen ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=1968 creation date=2017-06-25 touchdate=2025-05-10 11:36:26.000)
≈ 73 relations sortantes

  1. en:mine regimen -- r_associated #0: 39 / 1 -> en:macop-b regimen
    n1=en:mine regimen | n2=en:macop-b regimen | rel=r_associated | relid=0 | w=39
  2. en:mine regimen -- r_associated #0: 39 / 1 -> en:promace-cytabom regimen
    n1=en:mine regimen | n2=en:promace-cytabom regimen | rel=r_associated | relid=0 | w=39
  3. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:av regimen
    n1=en:mine regimen | n2=en:av regimen | rel=r_associated | relid=0 | w=35
  4. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:chemotherapy regimen used to treat childhood non-hodgkin's lymphoma
    n1=en:mine regimen | n2=en:chemotherapy regimen used to treat childhood non-hodgkin's lymphoma | rel=r_associated | relid=0 | w=35
  5. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:chope regimen
    n1=en:mine regimen | n2=en:chope regimen | rel=r_associated | relid=0 | w=35
  6. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:cvp regimen
    n1=en:mine regimen | n2=en:cvp regimen | rel=r_associated | relid=0 | w=35
  7. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:f-machop regimen
    n1=en:mine regimen | n2=en:f-machop regimen | rel=r_associated | relid=0 | w=35
  8. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:fc regimen
    n1=en:mine regimen | n2=en:fc regimen | rel=r_associated | relid=0 | w=35
  9. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:pcr regimen
    n1=en:mine regimen | n2=en:pcr regimen | rel=r_associated | relid=0 | w=35
  10. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:r-epoch regimen
    n1=en:mine regimen | n2=en:r-epoch regimen | rel=r_associated | relid=0 | w=35
  11. en:mine regimen -- r_associated #0: 35 / 0.897 -> en:thalidomide-rituximab regimen
    n1=en:mine regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=35
  12. en:mine regimen -- r_associated #0: 34 / 0.872 -> en:abv regimen
    n1=en:mine regimen | n2=en:abv regimen | rel=r_associated | relid=0 | w=34
  13. en:mine regimen -- r_associated #0: 34 / 0.872 -> en:calgb 9251 regimen
    n1=en:mine regimen | n2=en:calgb 9251 regimen | rel=r_associated | relid=0 | w=34
  14. en:mine regimen -- r_associated #0: 34 / 0.872 -> en:chlvpp regimen
    n1=en:mine regimen | n2=en:chlvpp regimen | rel=r_associated | relid=0 | w=34
  15. en:mine regimen -- r_associated #0: 34 / 0.872 -> en:chop regimen
    n1=en:mine regimen | n2=en:chop regimen | rel=r_associated | relid=0 | w=34
  16. en:mine regimen -- r_associated #0: 34 / 0.872 -> en:mitoxantrone hydrochloride
    n1=en:mine regimen | n2=en:mitoxantrone hydrochloride | rel=r_associated | relid=0 | w=34
  17. en:mine regimen -- r_associated #0: 34 / 0.872 -> en:r-fm regimen
    n1=en:mine regimen | n2=en:r-fm regimen | rel=r_associated | relid=0 | w=34
  18. en:mine regimen -- r_associated #0: 34 / 0.872 -> en:stanford v regimen
    n1=en:mine regimen | n2=en:stanford v regimen | rel=r_associated | relid=0 | w=34
  19. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:codox-m regimen
    n1=en:mine regimen | n2=en:codox-m regimen | rel=r_associated | relid=0 | w=32
  20. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:codox-m/ivac regimen
    n1=en:mine regimen | n2=en:codox-m/ivac regimen | rel=r_associated | relid=0 | w=32
  21. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:evap regimen
    n1=en:mine regimen | n2=en:evap regimen | rel=r_associated | relid=0 | w=32
  22. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:hypercvad regimen
    n1=en:mine regimen | n2=en:hypercvad regimen | rel=r_associated | relid=0 | w=32
  23. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:hypercvad/hd mtx arac regimen
    n1=en:mine regimen | n2=en:hypercvad/hd mtx arac regimen | rel=r_associated | relid=0 | w=32
  24. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:ifosfamide
    n1=en:mine regimen | n2=en:ifosfamide | rel=r_associated | relid=0 | w=32
  25. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:m-bacop regimen
    n1=en:mine regimen | n2=en:m-bacop regimen | rel=r_associated | relid=0 | w=32
  26. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:r-ice regimen
    n1=en:mine regimen | n2=en:r-ice regimen | rel=r_associated | relid=0 | w=32
  27. en:mine regimen -- r_associated #0: 32 / 0.821 -> en:refractory non-hodgkin lymphoma
    n1=en:mine regimen | n2=en:refractory non-hodgkin lymphoma | rel=r_associated | relid=0 | w=32
  28. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:acvbp regimen
    n1=en:mine regimen | n2=en:acvbp regimen | rel=r_associated | relid=0 | w=31
  29. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:cnop regimen
    n1=en:mine regimen | n2=en:cnop regimen | rel=r_associated | relid=0 | w=31
  30. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:dhap regimen
    n1=en:mine regimen | n2=en:dhap regimen | rel=r_associated | relid=0 | w=31
  31. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:eva regimen
    n1=en:mine regimen | n2=en:eva regimen | rel=r_associated | relid=0 | w=31
  32. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:fnd regimen
    n1=en:mine regimen | n2=en:fnd regimen | rel=r_associated | relid=0 | w=31
  33. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:magrath regimen
    n1=en:mine regimen | n2=en:magrath regimen | rel=r_associated | relid=0 | w=31
  34. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:mini-beam regimen
    n1=en:mine regimen | n2=en:mini-beam regimen | rel=r_associated | relid=0 | w=31
  35. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:mitoguazone
    n1=en:mine regimen | n2=en:mitoguazone | rel=r_associated | relid=0 | w=31
  36. en:mine regimen -- r_associated #0: 31 / 0.795 -> en:rf regimen
    n1=en:mine regimen | n2=en:rf regimen | rel=r_associated | relid=0 | w=31
  37. en:mine regimen -- r_associated #0: 30 / 0.769 -> en:copp-abvd regimen
    n1=en:mine regimen | n2=en:copp-abvd regimen | rel=r_associated | relid=0 | w=30
  38. en:mine regimen -- r_associated #0: 30 / 0.769 -> en:m-bacod regimen
    n1=en:mine regimen | n2=en:m-bacod regimen | rel=r_associated | relid=0 | w=30
  39. en:mine regimen -- r_associated #0: 30 / 0.769 -> en:mopp regimen
    n1=en:mine regimen | n2=en:mopp regimen | rel=r_associated | relid=0 | w=30
  40. en:mine regimen -- r_associated #0: 30 / 0.769 -> en:r-fcm regimen
    n1=en:mine regimen | n2=en:r-fcm regimen | rel=r_associated | relid=0 | w=30
  41. en:mine regimen -- r_associated #0: 30 / 0.769 -> en:vim-d regimen
    n1=en:mine regimen | n2=en:vim-d regimen | rel=r_associated | relid=0 | w=30
  42. en:mine regimen -- r_associated #0: 29 / 0.744 -> en:antineoplastic combined chemotherapy protocols
    n1=en:mine regimen | n2=en:antineoplastic combined chemotherapy protocols | rel=r_associated | relid=0 | w=29
  43. en:mine regimen -- r_associated #0: 29 / 0.744 -> en:beacopp regimen
    n1=en:mine regimen | n2=en:beacopp regimen | rel=r_associated | relid=0 | w=29
  44. en:mine regimen -- r_associated #0: 29 / 0.744 -> en:copp regimen
    n1=en:mine regimen | n2=en:copp regimen | rel=r_associated | relid=0 | w=29
  45. en:mine regimen -- r_associated #0: 29 / 0.744 -> en:etoposide
    n1=en:mine regimen | n2=en:etoposide | rel=r_associated | relid=0 | w=29
  46. en:mine regimen -- r_associated #0: 29 / 0.744 -> en:eva-chlvpp regimen
    n1=en:mine regimen | n2=en:eva-chlvpp regimen | rel=r_associated | relid=0 | w=29
  47. en:mine regimen -- r_associated #0: 29 / 0.744 -> en:ifosfamide-vinorelbine regimen
    n1=en:mine regimen | n2=en:ifosfamide-vinorelbine regimen | rel=r_associated | relid=0 | w=29
  48. en:mine regimen -- r_associated #0: 29 / 0.744 -> en:refractory hodgkin lymphoma
    n1=en:mine regimen | n2=en:refractory hodgkin lymphoma | rel=r_associated | relid=0 | w=29
  49. en:mine regimen -- r_associated #0: 28 / 0.718 -> en:abvd regimen
    n1=en:mine regimen | n2=en:abvd regimen | rel=r_associated | relid=0 | w=28
  50. en:mine regimen -- r_associated #0: 28 / 0.718 -> en:carboplatin/etoposide/melphalan regimen
    n1=en:mine regimen | n2=en:carboplatin/etoposide/melphalan regimen | rel=r_associated | relid=0 | w=28
  51. en:mine regimen -- r_associated #0: 28 / 0.718 -> en:chemotherapy regimen used to treat childhood hodgkins lymphoma
    n1=en:mine regimen | n2=en:chemotherapy regimen used to treat childhood hodgkins lymphoma | rel=r_associated | relid=0 | w=28
  52. en:mine regimen -- r_associated #0: 28 / 0.718 -> en:epoch regimen
    n1=en:mine regimen | n2=en:epoch regimen | rel=r_associated | relid=0 | w=28
  53. en:mine regimen -- r_associated #0: 28 / 0.718 -> en:mopp/abv hybrid regimen
    n1=en:mine regimen | n2=en:mopp/abv hybrid regimen | rel=r_associated | relid=0 | w=28
  54. en:mine regimen -- r_associated #0: 28 / 0.718 -> en:r-cvp regimen
    n1=en:mine regimen | n2=en:r-cvp regimen | rel=r_associated | relid=0 | w=28
  55. en:mine regimen -- r_associated #0: 28 / 0.718 -> en:recurrent adult non-hodgkin lymphoma
    n1=en:mine regimen | n2=en:recurrent adult non-hodgkin lymphoma | rel=r_associated | relid=0 | w=28
  56. en:mine regimen -- r_associated #0: 27 / 0.692 -> en:cde regimen
    n1=en:mine regimen | n2=en:cde regimen | rel=r_associated | relid=0 | w=27
  57. en:mine regimen -- r_associated #0: 27 / 0.692 -> en:eshap regimen
    n1=en:mine regimen | n2=en:eshap regimen | rel=r_associated | relid=0 | w=27
  58. en:mine regimen -- r_associated #0: 27 / 0.692 -> en:ice regimen
    n1=en:mine regimen | n2=en:ice regimen | rel=r_associated | relid=0 | w=27
  59. en:mine regimen -- r_associated #0: 27 / 0.692 -> en:recurrent adult hodgkin lymphoma
    n1=en:mine regimen | n2=en:recurrent adult hodgkin lymphoma | rel=r_associated | relid=0 | w=27
  60. en:mine regimen -- r_associated #0: 27 / 0.692 -> en:vinblastine
    n1=en:mine regimen | n2=en:vinblastine | rel=r_associated | relid=0 | w=27
  61. en:mine regimen -- r_associated #0: 26 / 0.667 -> en:mesna
    n1=en:mine regimen | n2=en:mesna | rel=r_associated | relid=0 | w=26
  62. en:mine regimen -- r_associated #0: 26 / 0.667 -> en:mopp/abvd alternating regimen
    n1=en:mine regimen | n2=en:mopp/abvd alternating regimen | rel=r_associated | relid=0 | w=26
  63. en:mine regimen -- r_associated #0: 26 / 0.667 -> en:r-chop regimen
    n1=en:mine regimen | n2=en:r-chop regimen | rel=r_associated | relid=0 | w=26
  64. en:mine regimen -- r_associated #0: 25 / 0.641 -> en:mine
    n1=en:mine regimen | n2=en:mine | rel=r_associated | relid=0 | w=25
  65. en:mine regimen -- r_associated #0: 20 / 0.513 -> en:avd regimen
    n1=en:mine regimen | n2=en:avd regimen | rel=r_associated | relid=0 | w=20
  66. en:mine regimen -- r_associated #0: 20 / 0.513 -> en:brentuximab vedotin regimen
    n1=en:mine regimen | n2=en:brentuximab vedotin regimen | rel=r_associated | relid=0 | w=20
  67. en:mine regimen -- r_associated #0: 20 / 0.513 -> en:epoch-o regimen
    n1=en:mine regimen | n2=en:epoch-o regimen | rel=r_associated | relid=0 | w=20
  68. en:mine regimen -- r_associated #0: 20 / 0.513 -> en:etoposide-vincristine-adriamycin regimen
    n1=en:mine regimen | n2=en:etoposide-vincristine-adriamycin regimen | rel=r_associated | relid=0 | w=20
  69. en:mine regimen -- r_associated #0: 20 / 0.513 -> en:methyl-gag
    n1=en:mine regimen | n2=en:methyl-gag | rel=r_associated | relid=0 | w=20
  70. en:mine regimen -- r_associated #0: 20 / 0.513 -> mesna
    n1=en:mine regimen | n2=mesna | rel=r_associated | relid=0 | w=20
  71. en:mine regimen -- r_associated #0: 20 / 0.513 -> mitoguazone
    n1=en:mine regimen | n2=mitoguazone | rel=r_associated | relid=0 | w=20
  72. en:mine regimen -- r_associated #0: 20 / 0.513 -> mitoguazones
    n1=en:mine regimen | n2=mitoguazones | rel=r_associated | relid=0 | w=20
  73. en:mine regimen -- r_associated #0: 20 / 0.513 -> vinblastine
    n1=en:mine regimen | n2=vinblastine | rel=r_associated | relid=0 | w=20
≈ 76 relations entrantes

  1. mesna --- r_associated #0: 57 --> en:mine regimen
    n1=mesna | n2=en:mine regimen | rel=r_associated | relid=0 | w=57
  2. en:mesna --- r_associated #0: 53 --> en:mine regimen
    n1=en:mesna | n2=en:mine regimen | rel=r_associated | relid=0 | w=53
  3. vinblastine --- r_associated #0: 48 --> en:mine regimen
    n1=vinblastine | n2=en:mine regimen | rel=r_associated | relid=0 | w=48
  4. en:vinblastine --- r_associated #0: 45 --> en:mine regimen
    n1=en:vinblastine | n2=en:mine regimen | rel=r_associated | relid=0 | w=45
  5. en:thalidomide-rituximab regimen --- r_associated #0: 37 --> en:mine regimen
    n1=en:thalidomide-rituximab regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=37
  6. en:acvbp regimen --- r_associated #0: 35 --> en:mine regimen
    n1=en:acvbp regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=35
  7. en:avd regimen --- r_associated #0: 35 --> en:mine regimen
    n1=en:avd regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=35
  8. en:etoposide-vincristine-adriamycin regimen --- r_associated #0: 35 --> en:mine regimen
    n1=en:etoposide-vincristine-adriamycin regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=35
  9. en:m-bacod regimen --- r_associated #0: 35 --> en:mine regimen
    n1=en:m-bacod regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=35
  10. en:antineoplastic combined chemotherapy protocols --- r_associated #0: 34 --> en:mine regimen
    n1=en:antineoplastic combined chemotherapy protocols | n2=en:mine regimen | rel=r_associated | relid=0 | w=34
  11. en:codox-m regimen --- r_associated #0: 34 --> en:mine regimen
    n1=en:codox-m regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=34
  12. en:promace-cytabom regimen --- r_associated #0: 32 --> en:mine regimen
    n1=en:promace-cytabom regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=32
  13. en:macop-b regimen --- r_associated #0: 31 --> en:mine regimen
    n1=en:macop-b regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=31
  14. en:magrath regimen --- r_associated #0: 31 --> en:mine regimen
    n1=en:magrath regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=31
  15. en:methyl-gag --- r_associated #0: 31 --> en:mine regimen
    n1=en:methyl-gag | n2=en:mine regimen | rel=r_associated | relid=0 | w=31
  16. en:mitoguazone --- r_associated #0: 31 --> en:mine regimen
    n1=en:mitoguazone | n2=en:mine regimen | rel=r_associated | relid=0 | w=31
  17. en:r-fcm regimen --- r_associated #0: 31 --> en:mine regimen
    n1=en:r-fcm regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=31
  18. mitoguazone --- r_associated #0: 31 --> en:mine regimen
    n1=mitoguazone | n2=en:mine regimen | rel=r_associated | relid=0 | w=31
  19. mitoguazones --- r_associated #0: 31 --> en:mine regimen
    n1=mitoguazones | n2=en:mine regimen | rel=r_associated | relid=0 | w=31
  20. en:chope regimen --- r_associated #0: 30 --> en:mine regimen
    n1=en:chope regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=30
  21. en:cnop regimen --- r_associated #0: 30 --> en:mine regimen
    n1=en:cnop regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=30
  22. en:epoch-o regimen --- r_associated #0: 30 --> en:mine regimen
    n1=en:epoch-o regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=30
  23. en:ifosfamide-vinorelbine regimen --- r_associated #0: 30 --> en:mine regimen
    n1=en:ifosfamide-vinorelbine regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=30
  24. en:eshap regimen --- r_associated #0: 29 --> en:mine regimen
    n1=en:eshap regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=29
  25. en:fc regimen --- r_associated #0: 29 --> en:mine regimen
    n1=en:fc regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=29
  26. en:hypercvad/hd mtx arac regimen --- r_associated #0: 29 --> en:mine regimen
    n1=en:hypercvad/hd mtx arac regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=29
  27. en:pcr regimen --- r_associated #0: 29 --> en:mine regimen
    n1=en:pcr regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=29
  28. en:chemotherapy regimen used to treat childhood non-hodgkin's lymphoma --- r_associated #0: 28 --> en:mine regimen
    n1=en:chemotherapy regimen used to treat childhood non-hodgkin's lymphoma | n2=en:mine regimen | rel=r_associated | relid=0 | w=28
  29. en:codox-m/ivac regimen --- r_associated #0: 28 --> en:mine regimen
    n1=en:codox-m/ivac regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=28
  30. en:rf regimen --- r_associated #0: 28 --> en:mine regimen
    n1=en:rf regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=28
  31. en:copp regimen --- r_associated #0: 27 --> en:mine regimen
    n1=en:copp regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=27
  32. en:dhap regimen --- r_associated #0: 27 --> en:mine regimen
    n1=en:dhap regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=27
  33. en:fnd regimen --- r_associated #0: 27 --> en:mine regimen
    n1=en:fnd regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=27
  34. en:abvd regimen --- r_associated #0: 26 --> en:mine regimen
    n1=en:abvd regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=26
  35. en:brentuximab vedotin regimen --- r_associated #0: 26 --> en:mine regimen
    n1=en:brentuximab vedotin regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=26
  36. en:carboplatin/etoposide/melphalan regimen --- r_associated #0: 26 --> en:mine regimen
    n1=en:carboplatin/etoposide/melphalan regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=26
  37. en:mopp/abvd alternating regimen --- r_associated #0: 26 --> en:mine regimen
    n1=en:mopp/abvd alternating regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=26
  38. en:r-fm regimen --- r_associated #0: 26 --> en:mine regimen
    n1=en:r-fm regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=26
  39. en:abv regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:abv regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  40. en:av regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:av regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  41. en:beacopp regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:beacopp regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  42. en:calgb 9251 regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:calgb 9251 regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  43. en:cde regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:cde regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  44. en:chemotherapy regimen used to treat childhood hodgkins lymphoma --- r_associated #0: 20 --> en:mine regimen
    n1=en:chemotherapy regimen used to treat childhood hodgkins lymphoma | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  45. en:chlvpp regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:chlvpp regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  46. en:chop regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:chop regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  47. en:copp-abvd regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:copp-abvd regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  48. en:cvp regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:cvp regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  49. en:epoch regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:epoch regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  50. en:etoposide --- r_associated #0: 20 --> en:mine regimen
    n1=en:etoposide | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  51. en:eva regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:eva regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  52. en:eva-chlvpp regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:eva-chlvpp regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  53. en:evap regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:evap regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  54. en:f-machop regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:f-machop regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  55. en:hypercvad regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:hypercvad regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  56. en:ice regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:ice regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  57. en:ifosfamide --- r_associated #0: 20 --> en:mine regimen
    n1=en:ifosfamide | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  58. en:m-bacop regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:m-bacop regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  59. en:mini-beam regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:mini-beam regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  60. en:mitoxantrone hydrochloride --- r_associated #0: 20 --> en:mine regimen
    n1=en:mitoxantrone hydrochloride | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  61. en:mopp regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:mopp regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  62. en:mopp/abv hybrid regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:mopp/abv hybrid regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  63. en:r-chop regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:r-chop regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  64. en:r-cvp regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:r-cvp regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  65. en:r-epoch regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:r-epoch regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  66. en:r-ice regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:r-ice regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  67. en:recurrent adult hodgkin lymphoma --- r_associated #0: 20 --> en:mine regimen
    n1=en:recurrent adult hodgkin lymphoma | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  68. en:recurrent adult non-hodgkin lymphoma --- r_associated #0: 20 --> en:mine regimen
    n1=en:recurrent adult non-hodgkin lymphoma | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  69. en:refractory hodgkin lymphoma --- r_associated #0: 20 --> en:mine regimen
    n1=en:refractory hodgkin lymphoma | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  70. en:refractory non-hodgkin lymphoma --- r_associated #0: 20 --> en:mine regimen
    n1=en:refractory non-hodgkin lymphoma | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  71. en:stanford v regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:stanford v regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  72. en:vim-d regimen --- r_associated #0: 20 --> en:mine regimen
    n1=en:vim-d regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=20
  73. Vinblastine --- r_associated #0: 10 --> en:mine regimen
    n1=Vinblastine | n2=en:mine regimen | rel=r_associated | relid=0 | w=10
  74. ifosfamide --- r_associated #0: 10 --> en:mine regimen
    n1=ifosfamide | n2=en:mine regimen | rel=r_associated | relid=0 | w=10
  75. étoposide --- r_associated #0: 10 --> en:mine regimen
    n1=étoposide | n2=en:mine regimen | rel=r_associated | relid=0 | w=10
  76. villeuse de la vessie (maladie) --- r_associated #0: 5 --> en:mine regimen
    n1=villeuse de la vessie (maladie) | n2=en:mine regimen | rel=r_associated | relid=0 | w=5
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr